AbbVie Files Suit Challenging CMS Botox Price Limits
AbbVie has taken the U.S. Department of Health and Human Services and the Centers for Medicare & Medicaid Services to federal court in Washington, D.C., seeking to overturn newly applied price controls for Botox. The company contends Botox qualifies as a plasma-derived product excluded from price controls under the Inflation Reduction Act of 2022 a…